Clinical Usefulness of Spectral-Domain Optical Coherence Tomography in Glaucoma and NAION.
The development of optical coherence tomography (OCT) has changed the clinical management of ophthalmic diseases by furthering the understanding of pathogenesis, as well as improving the monitoring of their progression and assisting in quantifying the response to treatment modalities in ophthalmic diseases. Initially, the two-dimensional configuration of the optic nerve head (ONH) and the thickness of the retinal nerve fiber layer (RNFL) were the main OCT structural parameters used in clinical management of optic nerve diseases. Now, with higher resolution power and faster acquisition times, the details of ONH and the retina including the macular area can be measured using spectral domain OCT (SD-OCT) with high reproducibility and increased diagnostic ability. OCT can provide structural information to improve the understanding and management of optic nerve diseases. In this review, we will briefly summarize the clinical applications of SD-OCT in glaucoma and nonarteritic anterior ischemic optic neuropathy, which are two representative optic nerve diseases.
Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Korea.
Tae Hee
TH
Lee
Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Korea.
Hwan
H
Heo
Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Korea.
Sang Woo
SW
Park
Glaucoma; Optic Nerve Diseases; Optic Neuropathy, Ischemic; Tomography, Optical Coherence
Optom Vis Sci. 2014 Nov;91(11):1320-7
25237762
Prog Brain Res. 2008;173:59-73
18929102
Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):983-9
26631135
Am J Ophthalmol. 2006 Nov;142(5):858-60
17056370
Ophthalmology. 2005 Jan;112(1):120-6
15629831
Br J Ophthalmol. 2012 Dec;96(12):1452-5
23018425
Invest Ophthalmol Vis Sci. 2011 Apr 14;52(5):2425-36
21493951
Arch Ophthalmol. 2008 Jun;126(6):812-5
18541844
J Glaucoma. 2014 Aug;23(6):341-6
23221905
J Glaucoma. 2014 Oct-Nov;23(8):e144-51
24240879
Ophthalmology. 2012 Apr;119(4):731-7
22264886
Arch Ophthalmol. 2009 Dec;127(12):1603-9
20008715
Ophthalmology. 2010 Jun;117(6):1177-1189.e4
20171740
Arch Ophthalmol. 2009 Jan;127(1):45-9
19139337
Optom Vis Sci. 2011 Jan;88(1):124-9
21037496
J Neuroophthalmol. 2016 Jun;36(2):141-6
26835663
Acta Ophthalmol. 2015 Jun;93(4):e301-5
25178150
Invest Ophthalmol Vis Sci. 2012 Jun 20;53(7):3817-26
22562510
Br J Ophthalmol. 2013 Aug;97(8):1045-50
23759443
Indian J Ophthalmol. 2011 Jan;59 Suppl:S59-68
21150036
Science. 1991 Nov 22;254(5035):1178-81
1957169
Arch Ophthalmol. 2006 Aug;124(8):1111-7
16908813
Prog Retin Eye Res. 2001 Sep;20(5):563-93
11470451
Ophthalmology. 2012 Feb;119(2):308-13
22182800
Invest Ophthalmol Vis Sci. 2011 Oct 21;52(11):8323-9
21917932
Graefes Arch Clin Exp Ophthalmol. 2014 Nov;252(11):1839-46
25107540
J Biomed Opt. 2007 Jul-Aug;12(4):041209
17867798
Ophthalmology. 2016 Jun;123(6):1201-10
27001534
Ophthalmology. 2003 Oct;110(10):2031-5
14522783
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4087-92
17724191
Am J Ophthalmol. 1985 Dec 15;100(6):769-76
4073173
Ophthalmology. 2012 Jun;119(6):1151-8
22365056
Ophthalmology. 2012 Sep;119(9):1858-66
22677426
Acta Ophthalmol. 2015 Aug;93(5):e356-65
25619801
Invest Ophthalmol Vis Sci. 2004 Mar;45(3):749-57; 748
14985286
J Glaucoma. 2012 Sep;21(7):498-504
21637115
Am J Ophthalmol. 2007 Feb;143(2):288-294
17157797
Ophthalmology. 2011 Feb;118(2):241-8.e1
20920824
Eye (Lond). 2011 Mar;25(3):269-77
21212798
Br J Ophthalmol. 2012 Nov;96(11):1420-5
22914498
Ophthalmology. 2009 Jul;116(7):1257-63, 1263.e1-2
19464061
Invest Ophthalmol Vis Sci. 2011 Aug 22;52(9):6558-64
21705690
Ophthalmology. 2007 Dec;114(12):2338-44
17719640
J Glaucoma. 2013 Dec;22(9):713-8
22668975
Acta Ophthalmol. 2012 Jun;90(4):310-5
20946342
Ophthalmology. 2011 Aug;118(8):1558-62
21529954